Q-omics provides the consensus-scored NT5C1B profile across patient tissues and cancer cell-line models. NT5C1B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, NT5C1B is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, NT5C1B RNA expression shows 19,067 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, HNSC, and THYM as cancer lineages where NT5C1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5C1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5C1B survival associations across molecular data types. NT5C1B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5C1B RNA expression–survival associations across cancer types. High NT5C1B expression shows unfavorable associations in LGG, CESC, LUAD and CHOL, but favorable associations in KIRC and HNSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for NT5C1B RNA expression.
This table summarizes NT5C1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NT5C1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5C1B shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in HNSC, LUSC and BLCA. The HNSC box plot shows higher NT5C1B RNA expression in tumor versus normal tissue (log2 FC = +0.318, t-test p < 0.001).
This table shows molecular features associated with NT5C1B in patient tissues and cancer cell lines. In patient samples, NT5C1B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NT5C1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
